Trial Profile

A clinical study of MemVax vaccine for COVID-19

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MemVax (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

05 Jun 2020 According to a Memgen company website, the company is planning to initiate this study in the second half of 2020.
05 Jun 2020 New trial record
02 Jun 2020 According to a Memgen media release, the company planning soon to initiate this study in collaboration with other companies developing complementary COVID-19 vaccines.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com